If you have been reading about c-Met receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
parietina, though they remain genetically distinct species with different morphological features and ecological preferences. The presence of crystals on the upper surface is a key characteristic that distinguishes both X. aureola and X. calcicola from X. parietina, which has a smooth upper surface. Another possible lookalike, Rusavskia elegans, has smaller convex lobes that measure up to 1.3 mm wide.
== Selected bibliography == Gitashri Naiya, Paromita Raha, Manas Mondal, Uttam Pal, Rajesh Saha, Susobhan Choudhury, Subrata Batabyal, Samir Kumar Pal, Dhananjay Bhattacharyya, Nakul Chandra Maiti, Siddhartha Roy (June 2016). "Conformational Selection Underpins Recognition of Multiple DNA sequences by Proteins and Consequent Functional Actions". Physical Chemistry Chemical Physics. 18 (31): 21618–21628. Bibcode:2016PCCP...1821618N. doi:10.1039/C6CP03278H. PMID 27426617.{{cite journal}}: CS1 maint: multiple names: authors list (link) Samir Kumar Pal, Susobhan Choudhury, Basusree Ghosh, Priya Singh, Raka Ghosh, Siddhartha Roy (June 2016). "Ultrafast Differential Flexibility of Cro-protein Binding Domains of Two Operator DNAs with Different Sequences". Physical Chemistry Chemical Physics. 18 (27): 17983–17990. Bibcode:2016PCCP...1817983C. doi:10.1039/C6CP02522F. PMID 27326896.{{cite journal}}: CS1 maint: multiple names: authors list (link) Sk Kayum Alam, Vinod Yadav, Swati Bajaj, Arindam Datta, Shamit Kumar Dutta, Madhumita Bhattacharyya, Santanu Bhattacharya, Subrata Debnath, Siddhartha Roy, Lisa A Boardman, Thomas Smyrk, Julian R. Molina, Saikat Chakrabarty, Shantanu Chowdhury, Debabrata Mukhopadhyay, Susanta Roychoudhury (April 2016). "DNA Damage-Induced Ephrin-B2 Reverse Signaling Promotes Chemoresistance and Drives EMT in Colorectal Carcinoma Harboring Mutant p53". Cell Death and Differentiation. 23 (4): 707–722. doi:10.1038/cdd.2015.133. PMC 4986638.
Emmanuel Philibert, also known under the nickname of Iron Head (Testa 'd Fer), made Turin the capital of the Duchy of Savoy in 1563. Piazza Reale (named Piazza San Carlo today) and Via Nuova (current Via Roma) were added along with the first enlargement of the walls, in the first half of the 17th century; in the same period the Palazzo Reale (Royal Palace of Turin) was also built. In the second half of that century, a second enlargement of the walls was planned and executed, with the building of the arcaded Via Po, connecting Piazza Castello with the bridge on the Po through the regular street grid. In 1706, during the Battle of Turin, the French besieged the city for 117 days without conquering it. By the Treaty of Utrecht the Duke of Savoy acquired Sicily, soon traded for Sardinia, and part of the former Duchy of Milan, and obtained the title of King of Sardinia; thus Turin became the capital of a European kingdom. The architect Filippo Juvarra began a major redesign of the city; Turin had about 90,000 inhabitants at the time.
== Governance and regulatory issues == Xenobiology might challenge the regulatory framework, as currently laws and directives deal with genetically modified organisms and do not directly mention chemically or genomically modified organisms. Taking into account that real xenobiology organisms are not expected in the next few years, policy makers do have some time at hand to prepare themselves for an upcoming governance challenge. Since 2012, the following groups have picked up the topic as a developing governance issue: policy advisers in the US, four National Biosafety Boards in Europe, the European Molecular Biology Organisation, and the European Commission's Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) in three opinions (Definition, risk assessment methodologies and safety aspects, and risks to the environment and biodiversity related to synthetic biology and research priorities in the field of synthetic biology.).
=== Surprise cyber attack === The idea of a "cyber Pearl Harbor" has been debated by scholars, drawing an analogy to the historical act of war. Others have used "cyber 9/11" to draw attention to the nontraditional, asymmetric, or irregular aspect of cyber action against a state.
Sources: en.wikipedia.org
== Products == The Company manufactures and sells 39 pharmaceuticals marketed under various brands. Of these products, 33 are prescription pharmaceuticals and six are over-the-counter (OTC) pharmaceuticals. In addition, it is also the distributor of Yingtaiqing-branded generic diclofenac sodium sustained-release capsules, the Faneng-branded generic alfacalcidol soft capsules and the Yineng-branded generic lentinan injection, all of which are prescription pharmaceuticals manufactured by independent third parties.
Democrats had differing views on why Harris lost the election. Vermont Senator Bernie Sanders blamed Democrats for having abandoned the working class. Democratic National Committee chair Jaime Harrison dismissed Sanders' criticism. Former House Speaker Nancy Pelosi also disagreed with Sanders, blaming the party's loss on Biden's late exit and the lack of an open Democratic primary. Senator Chris Murphy (D-CT) believed that the Democrats could not connect to a large number of voters and should embrace populism going forward. Representative Ritchie Torres (D-NY) attributed Trump's victory to public discontent over inflation and immigration; he asserted that Harris ran an effective campaign, but could not overcome a difficult electoral environment.
=== EC 1.16.1 With NAD+ or NADP+ as acceptor === EC 1.16.1.1: mercury(II) reductase EC 1.16.1.2: diferric-transferrin reductase EC 1.16.1.3: deleted since no specific enzyme catalysing this activity has been identified EC 1.16.1.4: cob(II)alamin reductase EC 1.16.1.5: deleted since the enzyme the entry was based on was later shown to be EC 1.2.1.51, pyruvate dehydrogenase (NADP+). EC 1.16.1.6: cyanocobalamin reductase (cyanide-eliminating) EC 1.16.1.7: ferric-chelate reductase EC 1.16.1.8: [methionine synthase] reductase EC 1.16.1.9: ferric-chelate reductase (NADPH) EC 1.16.1.10: ferric-chelate reductase [NAD(P)H]
=== Classification === Malignant peripheral nerve sheath tumors are a rare type of cancer that arise from the soft tissue that surrounds nerves. They are a type of sarcoma. Most malignant peripheral nerve sheath tumors arise from the nerve plexuses that distribute nerves into the limbs—the brachial and lumbar plexuses—or from nerves as they arise from the trunk.
Appropriate technology options in water treatment include both community-scale and household-scale point-of-use (POU) or self-supply designs. Such designs may employ solar water disinfection methods, using solar irradiation to inactivate harmful waterborne microorganisms directly, mainly by the UV-A component of the solar spectrum, or indirectly through the presence of an oxide photocatalyst, typically supported TiO2 in its anatase or rutile phases. Despite progress in SODIS technology, military surplus water treatment units like the ERDLator are still frequently used in developing countries. Newer military style Reverse Osmosis Water Purification Units (ROWPU) are portable, self-contained water treatment plants are becoming more available for public use. For waterborne disease reduction to last, water treatment programs that research and development groups start in developing countries must be sustainable by the citizens of those countries. This can ensure the efficiency of such programs after the departure of the research team, as monitoring is difficult because of the remoteness of many locations. Energy Consumption: Water treatment plants can be significant consumers of energy. In California, more than 4% of the state's electricity consumption goes towards transporting moderate quality water over long distances, treating that water to a high standard. In areas with high quality water sources which flow by gravity to the point of consumption, costs will be much lower. Much of the energy requirements are in pumping.
Sources: en.wikipedia.org
Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.
. It is unitless. A "high-resolution" mass analyzer typically has resolution >1 million. Concretely, that means it can resolve two peaks at ~1 kDa, differing by just ~1 mDa. The absolute accuracy is the ratio of the m/z measurement error to the true m/z. It is defined as
The 1860 civil conflict in Mount Lebanon and Damascus (also called the 1860 Syrian Civil War) was a civil conflict in Mount Lebanon during Ottoman rule in 1860–1861 fought mainly between the local Druze and Christians. Following decisive Druze victories and massacres against the Christians, the conflict spilled over into other parts of Ottoman Syria, particularly Damascus, where thousands of Christian residents (10,0000) were killed by Muslim and Druze militiamen. The fighting precipitated a French-led international military intervention. Bitter conflicts between Christians and Druzes, which had been simmering under Ibrahim Pasha's rule (mostly centred on the firmans of 1839 and, more decisively, of 1856, which equalised the status of Muslim and non-Muslim subjects, the former resenting their implied loss of superiority) resurfaced under the new emir (Bashir Shihab III). The sultan deposed Bashir III on 13 January 1842 and appointed Omar Pasha as governor of Mount Lebanon. Representatives of the European powers proposed to the sultan that Mount Lebanon be partitioned into Christian and Druze sections. On 7 December 1842, the sultan adopted the proposal and asked the governor of Damascus to divide the region into two districts: a northern district under a Christian deputy governor and a southern district under a Druze deputy governor. The arrangement came to be known as the "Double Qaimaqamate". Both officials were to be responsible to the governor of Sidon, who resided in Beirut. The Beirut-Damascus highway was the dividing line between the two districts.
Experts in the United Kingdom have suggested that some psychoactive drugs that may be causing less harm to fewer users (although they are also used less frequently in the first place) are cannabis, psilocybin mushrooms, LSD, and MDMA; however, these drugs have risks and side effects of their own.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.